Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine. [ News Medical Life Sciences-McMaster Unviersity]

The AeroVax study, supported by $8M in funding from the Canadian Institutes of Health Research (CIHR), will test needle-free vaccines developed to provide protection from SARS-CoV-2.

Led by Fiona Smaill and Zhou Xing, members of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR) at McMaster, the multi-centre trial will evaluate the new vaccine in a broad study group, while also confirming safety.

Findings from pre-clinical studies and the soon-to-be-published data from the phase-1 trial indicate that McMaster's inhaled vaccine is more effective at inducing immune responses than traditional injected vaccines are, because it directly targets the lungs and upper airways — where the virus first enters the body.

More>

###